FOSUN PHARMA (02196.HK): FKC516 Injection Enters Phase II Trial for Relapsed or Refractory B-Cell NHL

NewTimeSpace News: On 12 November 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) published an overseas regulatory announcement under Rule 13.10B, reproducing its Shanghai Stock Exchange notice on clinical trial progress for a subsidiary's product. Its controlled subsidiary Fosun Kite (Shanghai) Biotechnology Co., Ltd. has launched a Phase II clinical trial in the PRC for FKC516 injection in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

The announcement disclosed that FKC516 is a licensed-in CD20-targeting autologous CAR-T cell therapy for which the Group holds exclusive global development and commercialisation rights across all diseases. As at September 2026, cumulative research and development spending on FKC516 was about RMB 13.37 million, including licensing fees and unaudited.

The Company stated that, as at the date of the announcement, no CAR-T product targeting the same antigen had been approved in the PRC. It cautioned that FKC516 must complete clinical trials in the PRC and obtain approval from the national drug review authority before marketing, and that drug development from research through trials to launch is lengthy and involves many uncertainties.